临床专家

王峰

职务：院长助理、内科主任
职称：教授、主任医师、研究员

专长

消化系统肿瘤的内科治疗和研究

一、个人简介

美国MD Anderson 肿瘤中心博士（PhD.）、中山大学临床医学博士（MD.）。华南恶性肿瘤防治全国重点实验室PI，国家杰出青年科学基金获得者、国家级高层次人才。中国抗癌协会青年理事会副理事长、中国临床肿瘤学会（CSCO）理事、广东省抗癌协会大肠癌专业委员会副主任委员等。

长期致力于消化道肿瘤的精准化治疗和免疫治疗增效，主持国家自然科学基金国际（地区）合作与交流项目、面上项目在内的科研基金 14 项。以通讯或第一作者，在Cell, Nature Medicine（3篇）, Cancer Cell（2篇）, Journal of Clinical Oncology, JAMA Oncology, Annals of Oncology, The Lancet Gastroenterology and Hepatology 等杂志发表论文 60 篇，ESI高被引5篇。10项研究被写入美国NCCN、ASCO，中国CSCO、CACA等9部国内外权威指南。获得国家发明专利授权9项，荣获国家科技进步奖二等奖、教育部科技进步一等奖、中华医学会科技进步一等奖、教育部科技进步奖一等奖、中国医学科学院“2022年度重要医学进展”奖、广东青年五四奖章、第六届“科学探索奖”等省部级奖项。多次获“国之名医”、“人民好医生”、“中国抗癌协会青年科学家”等荣誉称号。近5年7次受邀在美国 ASCO 、欧洲 ESMO 年会、日本JSCO年会等重大国际会议做口头报告。

 

二、学术兼职

1. 中国抗癌协会青年理事会副理事长

2. 中国临床肿瘤学会（CSCO）理事

3. 广东省抗癌协会大肠癌专业委员会副主任委员

4. 广东省抗癌协会多原发和不明原发肿瘤专业委员会副主任委员

5. 广东省抗癌协会肿瘤转移专业委员会常务委员

6. 广东省肿瘤性疾病医疗质量控制中心结直肠癌专家委员会常务委员

7. 广东省研究型医院学会理事等

 

三、主持科研项目

1. 国家自然科学基金委员会，国家杰出青年科学基金，82425048，逆转消化道肿瘤免疫治疗抵抗的临床转化研究

2. 国家自然科学基金委员会，国际(地区)合作与交流项目，82061160373，染色体11q13区段扩增介导食道鳞癌对PD-1抗体耐药的机制研究

3. 国家自然科学基金委员会，面上项目，81872011，PDE3A促进食道小细胞癌发生发展的机制和靶向治疗研究

4. 广州市科技创新委员会，重点研发计划, 202206080011，消化道肿瘤免疫治疗疗效及安全性预测模型的建立及应用

5. 北京市希思科临床肿瘤学研究基金会，重点课题，Y-QL202202-0089，评估西达本胺+信迪利单抗+贝伐珠单抗治疗对比标准二线治疗FOLFIRI+贝伐珠单抗在一线含奥沙利铂标准治疗失败的晚期微卫星稳定（MSS/pMMR）的结直肠癌受试者的随机、对照、多中心Ⅲ期临床研究

6. 广东省食道癌研究所科技计划，面上项目，M201905，染色体11q13区段扩增促进食道鳞癌对PD-1抗体耐药的机制研究

7. 中山大学，中山大学临床医学研究5010计划项目，2018014 一项比较静脉大剂量维生素C联合 FOLFOX +/-贝伐珠单抗对比FOLFOX +/-贝伐珠单抗一线治疗既往未接受过转移性疾病治疗 的转移性结直肠癌的随机、开放、多中心Ⅲ期临床研究

8. 国家自然科学基金委员会，青年科学基金，81302194，活性氧-NFkB信号通路在脑胶质瘤干细胞分化中的作用及其调控机制等

 

四、所获荣誉和奖项

1. 2019年度国家科学技术进步奖二等奖（第二完成人）

2. 2018年度中华医学科技奖一等奖（第三完成人）

3. 2018年度教育部科技进步奖一等奖（第四完成人）

4. 2018年度广东省科技进步一等奖（第四完成人）

5. 第六届“科学探索奖”

6. 中国医学科学院“中国2022年度重要医学进展”奖

7. 中国抗癌协会青年科学家奖

8. 第二十五届“广东青年五四奖章”

9. 国之名医

10. 人民好医生（胃癌、食管癌）领域等

 

五、代表性文章

1. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Yuan SQ, Nie RC, Jin Y, Liang CC, Li YF, Jian R, Sun XW, Chen YB, Guan WL, Wang ZX, Qiu HB, Wang W, Chen S, Zhang DS, Ling YH, Xi SY, Cai MY, Huang CY, Yang QX, Liu ZM, Guan YX, Chen YM, Li JB, Tang XW, Peng JS, Zhou ZW, Xu RH*, Wang F*. Nat Med. 2024a.

2. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Wang F*, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, Chen YX, Huang RJ, Guan WL, Li JB, Li YH, Wang FH, Hu XH, Zhang YQ, Qiu MZ, Liu LL, Wang ZX, Ren C, Wang DS, Zhang DS, Wang ZQ, Liao WT, Tian L, Zhao Q, Xu RH*. Nat Med. 2024b.

3. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Wang F, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Shu Y, Zhao F, Cheng Y, Ye F, Gu K, Zhang T, Pan H, Zhong H, Zhou F, Qin Y, Yang L, Mao W, Li Q, Dai W, Li W, Wang S, Tang Y, Ma D, Yin X, Deng Y, Yuan Y, Li M, Hu W, Chen D, Li G, Liu Q, Tan P, Fan S, Shi M, Su W, Xu RH. Nat Med. 2024c.

4. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. Wu HX, Pan YQ, He Y, Wang ZX, Guan WL, Chen YX, Yao YC, Shao NY, Xu RH*, Wang F*. J Clin Oncol. 2023.

5. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, Quan TT, Xi SY, Zhang HZ, Pan ZZ, Wang F*, Xu RH*. Lancet Gastroenterol Hepatol. 2023.

6. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Chen YX, Wang ZX, Jin Y, Zhao Q, Liu ZX, Zuo ZX, Ju HQ, Cui C, Yao J, Zhang Y, Li M, Feng J, Tian L, Xia XJ, Feng H, Yao S, Wang FH, Li YH, Wang F*, Xu RH*. Cancer Cell. 2023.

7. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Yuan SQ, Nie RC, Huang YS, Chen YB, Wang SY, Sun XW, Li YF, Liu ZK, Chen YX, Yao YC, Xu Y, Qiu HB, Liang Y, Wang W, Liu ZX, Zhao Q, Xu RH*, Zhou ZW*, Wang F*. Cancer Commun (Lond). 2023. 

8. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH*, Wang F*. Cancer Cell. 2022.

9. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. Yao YC, Jin Y, Lei XF, Wang ZX, Zhang DS, Wang FH, Li YH, Xu RH*, Wang F*. J Cancer. 2022.

10. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer. Wang F, He MM, Xiao J, Zhang YQ, Yuan XL, Fang WJ, Zhang Y, Wang W, Hu XH, Ma ZG, Yao YC, Zhuang ZX, Zhou FX, Ying JE, Yuan Y, Zou QF, Guo ZQ, Wu XY, Jin Y, Mai ZJ, Wang ZQ, Qiu H, Guo Y, Shi SM, Chen SZ, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH*. Clin Cancer Res. 2022.

11. Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer. Zhao Q, Wang F*, Chen YX, Chen S, Yao YC, Zeng ZL, Jiang TJ, Wang YN, Wu CY, Jing Y, Huang YS, Zhang J, Wang ZX, He MM, Pu HY, Mai ZJ, Wu QN, Long R, Zhang X, Huang T, Xu M, Qiu MZ, Luo HY, Li YH, Zhang DS, Jia WH, Chen G, Ding PR, Li LR, Lu ZH, Pan ZZ, Xu RH*. Nat Commun. 2022.

12. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Wang F*, Huang YS, Wu HX, Wang ZX, Jin Y, Yao YC, Chen YX, Zhao Q, Chen S, He MM, Luo HY, Qiu MZ, Wang DS, Wang FH, Xu M, Li YH, Xu RH*. Gut. 2022.

13. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, Li L, Ding P, Zhao Q, Li Y, Wang D, Shao Y, Bao H, Pan Z, Ding KF, Cai S, Wang F*, Xu RH*. J Hematol Oncol. 2021.

14. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. Chen YX, Wang ZX, Yuan SQ, Jiang TJ, Huang YS, Xu RH*, Wang F*, Zhao Q*. Clin Transl Med. 2021.

15. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, Lv ZD, Wang DS, Li YH, Zhang DS, Xu RH*. Cell Rep Med. 2021.

16. Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. Jiang TJ, Wang F, Wang YN, Hu JJ, Ding PR, Lin JZ, Pan ZZ, Chen G, Shao JY, Xu RH, Zhao Q, Wang F*. Cancer Commun (Lond). 2020.

17. Expert opinions on immunotherapy for patients with colorectal cancer. Wang F, Wang ZX, Chen G, Luo HY, Zhang DS, Qiu MZ, Wang DS, Pan ZZ, Shen L, Li J, Zhang SZ, Xu RH*. Cancer Commun (Lond). 2020.

18. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Wang YN, Lu YX, Liu J, Jin Y, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH, Wang F*. Oncogene. 2020.

19. Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. Wang F, Liu TS, Yuan XL, Luo HY, Gu KS, Yuan Y, Deng YH, Xu JM, Bai YX, Wang Y, Liao WJ, Zhang HL, Bi F, Wang BM, Zhuang ZX, Jiang TJ, Xu RH*. Am J Cancer Res. 2020.

20. Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment. Zhao Q, Chen YX, Wu QN, Zhang C, Liu M, Wang YN, Feng YF, Hu JJ, Fu JH, Yang H, Qi JJ, Wang ZX, Lu YX, Sheng H, Liu ZX, Zuo ZX, Zheng J, Yun JP, Bei JX, Jia WH, Lin DX, Xu RH*, Wang F*. Clin Transl Immunology. 2020.

21. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH*. JAMA Oncology. 2019.

22. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH*. Annals of Oncology. 2019.

23. The genomic landscape of small cell carcinoma of the esophagus. Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX, Xu RH*. Cell Research. 2018.

 

 

更新时间：2024.09.06

加载更多

Wang Feng

Department: Medical Oncology

Title: Professor, Assistant President and Director

Email: wangfeng@sysucc.org.cn

Mailing address：651 Dongfeng East Road, Guangzhou 510060, P. R. China

Profile: Dr. Feng Wang is currently a professor, assistant president and director in the Department of Medical Oncology at Sun Yat-Sen University Cancer Center, Guangzhou, China. Awarded The National Science Fund for Distinguished Young Scholars. She holds many academic posts, including the National high-level talents, Vice Chairman of Youth Council of China Anti-Cancer Association, Member of the Chinese Society of Clinical Oncology (CSCO) and deputy Chairman of the Colorectal Cancer Professional Committee of Guangdong Anticancer Association etc. She has extensive experience and expertise in the field of Precision treatment and immunotherapy for digestive tract tumors. Dr Wang sees more than thousands of patients with gastrointestinal cancers annually and has initiated or participated in many investigators initiated and NMPA approved clinical trials. She presides over 14 programs including the international (regional) cooperation and exchange program, and general program from the national natural science foundation of China. Dr. Wang has published over 60 articles, Act as corresponding/co-corresponding or first author, such as Nature Medicine（3 pieces）, Cancer Cell（2 pieces）, Journal of Clinical Oncology, JAMA Oncology, Annals of Oncology, The Lancet Gastroenterology and Hepatology, The Lancet Gastroenterology and Hepatology, etc. 5 articles were H-cited by ESI. 10 studies have been written into 9 authoritative guides at home and abroad, such as NCCN, ASCO, CSCO, CACA, etc. She was awarded 9 national invention patents and many prizes including the Second Prize of National Science and Technology Progress Award, First prize of Science and Technology Progress Award of Ministry of Education, First Prize of Chinese Medical Science and Technology Award, the First Prize of Guangdong Province Science and Technology Progress Award, "Important Medical Progress 2022" Award of Chinese Academy of Medical Sciences, Guangdong Youth May Fourth Medal, The 6th “XPLORER PRIZE”etc. She has won many honorary titles such as "National Famous Doctor", "People's Good Doctor" and "Young Scientist of China Anti-Cancer Association", and has been invited to invited to make oral presentations at major international conferences such as American ASCO, AACR Annual Meeting, European ESMO Annual Meeting, and China CSCO Annual Meeting.

 

Research Interest(s): Medical treatment and translational study of gastrointestinal neoplasm.

 

Education: 

UT M.D. Anderson Cancer Center, PhD                  Sep 2008-Jun 2012

Sun Yat-sen University Cancer Center, MS              Sep 2005-Jun 2008

Jiangxi Medical College, Bachelor of Medicine       Sep 2000-Jul 2005

 

Publications:

  1. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Yuan SQ, Nie RC, Jin Y, Liang CC, Li YF, Jian R, Sun XW, Chen YB, Guan WL, Wang ZX, Qiu HB, Wang W, Chen S, Zhang DS, Ling YH, Xi SY, Cai MY, Huang CY, Yang QX, Liu ZM, Guan YX, Chen YM, Li JB, Tang XW, Peng JS, Zhou ZW, Xu RH*, Wang F*. Nat Med. 2024a.
  2. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Wang F*, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, Chen YX, Huang RJ, Guan WL, Li JB, Li YH, Wang FH, Hu XH, Zhang YQ, Qiu MZ, Liu LL, Wang ZX, Ren C, Wang DS, Zhang DS, Wang ZQ, Liao WT, Tian L, Zhao Q, Xu RH*. Nat Med. 2024b.
  3. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Wang F, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Shu Y, Zhao F, Cheng Y, Ye F, Gu K, Zhang T, Pan H, Zhong H, Zhou F, Qin Y, Yang L, Mao W, Li Q, Dai W, Li W, Wang S, Tang Y, Ma D, Yin X, Deng Y, Yuan Y, Li M, Hu W, Chen D, Li G, Liu Q, Tan P, Fan S, Shi M, Su W, Xu RH. Nat Med. 2024c.
  4. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. Wu HX, Pan YQ, He Y, Wang ZX, Guan WL, Chen YX, Yao YC, Shao NY, Xu RH*, Wang F*. J Clin Oncol. 2023.
  5. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, Quan TT, Xi SY, Zhang HZ, Pan ZZ, Wang F*, Xu RH*. Lancet Gastroenterol Hepatol. 2023.
  6. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Chen YX, Wang ZX, Jin Y, Zhao Q, Liu ZX, Zuo ZX, Ju HQ, Cui C, Yao J, Zhang Y, Li M, Feng J, Tian L, Xia XJ, Feng H, Yao S, Wang FH, Li YH, Wang F*, Xu RH*. Cancer Cell. 2023.
  7. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Yuan SQ, Nie RC, Huang YS, Chen YB, Wang SY, Sun XW, Li YF, Liu ZK, Chen YX, Yao YC, Xu Y, Qiu HB, Liang Y, Wang W, Liu ZX, Zhao Q, Xu RH*, Zhou ZW*, Wang F*. Cancer Commun (Lond). 2023. 
  8. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH*, Wang F*. Cancer Cell. 2022.
  9. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. Yao YC, Jin Y, Lei XF, Wang ZX, Zhang DS, Wang FH, Li YH, Xu RH*, Wang F*. J Cancer. 2022.
  10. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer. Wang F, He MM, Xiao J, Zhang YQ, Yuan XL, Fang WJ, Zhang Y, Wang W, Hu XH, Ma ZG, Yao YC, Zhuang ZX, Zhou FX, Ying JE, Yuan Y, Zou QF, Guo ZQ, Wu XY, Jin Y, Mai ZJ, Wang ZQ, Qiu H, Guo Y, Shi SM, Chen SZ, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH*. Clin Cancer Res. 2022.
  11. Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer. Zhao Q, Wang F*, Chen YX, Chen S, Yao YC, Zeng ZL, Jiang TJ, Wang YN, Wu CY, Jing Y, Huang YS, Zhang J, Wang ZX, He MM, Pu HY, Mai ZJ, Wu QN, Long R, Zhang X, Huang T, Xu M, Qiu MZ, Luo HY, Li YH, Zhang DS, Jia WH, Chen G, Ding PR, Li LR, Lu ZH, Pan ZZ, Xu RH*. Nat Commun. 2022.
  12. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Wang F*, Huang YS, Wu HX, Wang ZX, Jin Y, Yao YC, Chen YX, Zhao Q, Chen S, He MM, Luo HY, Qiu MZ, Wang DS, Wang FH, Xu M, Li YH, Xu RH*. Gut. 2022.
  13. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, Li L, Ding P, Zhao Q, Li Y, Wang D, Shao Y, Bao H, Pan Z, Ding KF, Cai S, Wang F*, Xu RH*. J Hematol Oncol. 2021.
  14. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. Chen YX, Wang ZX, Yuan SQ, Jiang TJ, Huang YS, Xu RH*, Wang F*, Zhao Q*. Clin Transl Med. 2021.
  15. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, Lv ZD, Wang DS, Li YH, Zhang DS, Xu RH*. Cell Rep Med. 2021.
  16. Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. Jiang TJ, Wang F, Wang YN, Hu JJ, Ding PR, Lin JZ, Pan ZZ, Chen G, Shao JY, Xu RH, Zhao Q, Wang F*. Cancer Commun (Lond). 2020.
  17. Expert opinions on immunotherapy for patients with colorectal cancer. Wang F, Wang ZX, Chen G, Luo HY, Zhang DS, Qiu MZ, Wang DS, Pan ZZ, Shen L, Li J, Zhang SZ, Xu RH*. Cancer Commun (Lond). 2020.
  18. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Wang YN, Lu YX, Liu J, Jin Y, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH, Wang F*. Oncogene. 2020.
  19. Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. Wang F, Liu TS, Yuan XL, Luo HY, Gu KS, Yuan Y, Deng YH, Xu JM, Bai YX, Wang Y, Liao WJ, Zhang HL, Bi F, Wang BM, Zhuang ZX, Jiang TJ, Xu RH*. Am J Cancer Res. 2020.
  20. Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment. Zhao Q, Chen YX, Wu QN, Zhang C, Liu M, Wang YN, Feng YF, Hu JJ, Fu JH, Yang H, Qi JJ, Wang ZX, Lu YX, Sheng H, Liu ZX, Zuo ZX, Zheng J, Yun JP, Bei JX, Jia WH, Lin DX, Xu RH*, Wang F*. Clin Transl Immunology. 2020.
  21. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH*. JAMA Oncology. 2019.
  22. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH*. Annals of Oncology. 2019.
  23. The genomic landscape of small cell carcinoma of the esophagus. Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX, Xu RH*. Cell Research. 2018.